Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks. No clinical relapses were reported and a minority of patients showed Expanded Disability Status Scale (EDSS) progression. Monthly serum neurofilament light levels remained stable during extended intervals. Two (1.9%) of 107 patients with a follow-up magnetic resonance imaging (MRI) scan showed radiological disease activity. Personalized dosing of ocrelizumab could significantly extend intervals with low short-term disease activity incidence, encouraging future research on long-term safety and efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131403 | PMC |
| http://dx.doi.org/10.1177/13524585211028833 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and cognitive outcomes in Ocrelizumab-treated MS patients: Insights into the wearing-off phenomenon.
Mult Scler Relat Disord
August 2025
Sakarya University Faculty of Medicine, Department of Neurology, Sakarya, Turkey.
Objective: Ocrelizumab (OCR) has proven effective in altering the disease trajectory of multiple sclerosis (MS) patients. However, many patients experience a preinfusion "wearing-off phenomenon" (WoP) characterized by a resurgence of MS symptoms. This study aimed to investigate the relationships between WoP and various clinical, functional, and cognitive parameters and to compare demographic and radiological data between patients with and without WoP.
View Article and Find Full Text PDFEfficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis.
Mult Scler Relat Disord
August 2025
Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Background: Anti-CD20 monoclonal antibodies (mAbs) are highly effective in managing multiple sclerosis (MS), but may also increase infection risk and reduce vaccine responses. Alternative dosing strategies (ADS), such as extended-interval dosing (EID) and dose reduction, have been proposed to optimize safety and personalize treatment. This systematic review and meta-analysis was conducted to compare standard dosing strategies (SDS) to ADS of anti-CD20 mAbs in MS patients.
View Article and Find Full Text PDFTreatment outcomes in multiple sclerosis using reduced and extended interval ocrelizumab dosing.
Mult Scler Relat Disord
July 2025
Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia; School of Medicine, Gold Coast Campus, Griffith University QLD 4222, Australia.
Background: People with multiple sclerosis (pwMS) treated with ocrelizumab at our tertiary hospital during the COVID-19 pandemic were exposed to reduced dosing of 300 mg (RD) every 6 months, and also extended interval dosing (EID), due to concerns around infection risk and challenges attending hospital. We analysed clinical, MRI and laboratory outcomes to assess treatment effectiveness and safety compared with standard dosing (SD).
Methods: We collected data retrospectively on all people treated with ocrelizumab through our MS clinic from 01/01/2018 to 01/01/2024.
Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis.
Mult Scler
August 2025
Department of Neurology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany.
Background: Ocrelizumab (OCR) and ofatumumab (OFA)are approved and their differences in dosing route and interval allow personalized treatment. However, there are no data on whether lateral switches between both substances affect treatment effectiveness or safety.
Methods: We screened our local cohort of MS patients, who began OCR since 09/2020 or OFA since 09/2021.
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine.
Mult Scler Relat Disord
July 2025
Huygens & Versteegh B.V., Zwijndrecht, the Netherlands.
Background: Long-term treatment with standard interval dosing (SID) exposes MS patients to risks, but stopping treatment risks progression. Alternatives to stopping are 'exit strategies', such as extended interval dosing (EID) or de-escalating infection risks by switching to other DMTs.
Objective: To compare the cost-effectiveness of exit strategies for MS patients with stable disease on second line ocrelizumab or natalizumab.